CN1214039C - 3－氮－6,7－二氧甾族化合物及其应用 - Google Patents

3－氮－6,7－二氧甾族化合物及其应用 Download PDF

Info

Publication number
CN1214039C
CN1214039C CNB018101674A CN01810167A CN1214039C CN 1214039 C CN1214039 C CN 1214039C CN B018101674 A CNB018101674 A CN B018101674A CN 01810167 A CN01810167 A CN 01810167A CN 1214039 C CN1214039 C CN 1214039C
Authority
CN
China
Prior art keywords
compound
carbon
independently
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018101674A
Other languages
English (en)
Chinese (zh)
Other versions
CN1430625A (zh
Inventor
J·R·雷蒙德
C·E·卡瑟拉
沈亚平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflazyme Pharmaceuticals Ltd
Original Assignee
Inflazyme Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazyme Pharmaceuticals Ltd filed Critical Inflazyme Pharmaceuticals Ltd
Publication of CN1430625A publication Critical patent/CN1430625A/zh
Application granted granted Critical
Publication of CN1214039C publication Critical patent/CN1214039C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0063—Nitrogen and oxygen at position 2(3)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018101674A 2000-04-28 2001-04-30 3－氮－6,7－二氧甾族化合物及其应用 Expired - Fee Related CN1214039C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20061700P 2000-04-28 2000-04-28
US60/200,617 2000-04-28

Publications (2)

Publication Number Publication Date
CN1430625A CN1430625A (zh) 2003-07-16
CN1214039C true CN1214039C (zh) 2005-08-10

Family

ID=22742458

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018101674A Expired - Fee Related CN1214039C (zh) 2000-04-28 2001-04-30 3－氮－6,7－二氧甾族化合物及其应用

Country Status (33)

Country Link
US (4) US20040034216A1 (https=)
EP (1) EP1278763B1 (https=)
JP (1) JP2003531916A (https=)
KR (1) KR20030045671A (https=)
CN (1) CN1214039C (https=)
AP (1) AP1825A (https=)
AT (1) ATE353909T1 (https=)
AU (2) AU2001252084B2 (https=)
BG (1) BG107289A (https=)
BR (1) BR0110419A (https=)
CA (1) CA2418748A1 (https=)
CO (1) CO5590904A2 (https=)
DE (1) DE60126597T2 (https=)
DK (1) DK1278763T3 (https=)
DZ (1) DZ3355A1 (https=)
EE (1) EE200200613A (https=)
ES (1) ES2282247T3 (https=)
HR (1) HRP20020944A2 (https=)
HU (1) HUP0300908A2 (https=)
IL (2) IL152448A0 (https=)
MA (1) MA25808A1 (https=)
MX (1) MXPA02010645A (https=)
NO (1) NO324873B1 (https=)
NZ (1) NZ522181A (https=)
OA (1) OA12255A (https=)
PL (1) PL365798A1 (https=)
PT (1) PT1278763E (https=)
RU (1) RU2291873C2 (https=)
SK (1) SK15692002A3 (https=)
UA (1) UA79229C2 (https=)
WO (1) WO2001083512A1 (https=)
YU (1) YU88102A (https=)
ZA (1) ZA200208631B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
EP1278763B1 (en) * 2000-04-28 2007-02-14 Inflazyme Pharmaceuticals, Ltd. 3-nitrogen-6,7-dioxygen steroids and uses related thereto
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
CA2447780A1 (en) 2001-05-22 2002-11-28 Inflazyme Pharmaceuticals Ltd. Process for the production of 6, 7 - dihydroxy steroid compounds by allylic oxidation of steroid - 5 - ene compounds to steroid - 5 - ene - 7 - one compounds followed by hydroboration and oxidation and intermediates of this process
ATE413414T1 (de) * 2002-08-01 2008-11-15 Astellas Pharma Inc Kaliumabhängiger natrium-calcium-austauscher
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
FR2861077B1 (fr) * 2003-10-20 2006-03-03 Aventis Pharma Sa Formes cristallines du chlorydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol
US20080051382A1 (en) * 2003-10-20 2008-02-28 Inflazyme Pharmaceuticals Ltd. Crystalline Forms of 3-Beta-Amino 17-Methylene Androstane-6-Alpha 7-Beta-Diol Hydrochloride
WO2005037851A1 (fr) * 2003-10-20 2005-04-28 Inflazyme Pharmaceuticals, Ltd. Formes cristallines du chlorhydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
EP2217279B1 (en) * 2007-11-21 2017-11-01 The Procter & Gamble Company Preparations useful for treatment of cough
JP5655243B2 (ja) * 2009-10-19 2015-01-21 国立大学法人 熊本大学 インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤
ES2857626T3 (es) 2010-01-15 2021-09-29 Suzhou Neupharma Co Ltd Ciertas entidades químicas, composiciones y métodos
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
US9493503B2 (en) 2011-02-02 2016-11-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013165924A1 (en) * 2012-04-29 2013-11-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
TWI750197B (zh) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
MX2015012111A (es) 2013-03-14 2016-05-05 Aquinox Pharmaceuticals Canada Inc Moduladores de ship1 y métodos relacionados con éstos.
US10100056B2 (en) 2013-03-14 2018-10-16 Aquinox Pharmaceuticals (Canada) Inc. SHIP1 modulators and methods related thereto
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
CN104744547B (zh) * 2013-12-27 2017-02-15 天津医科大学 一种抗乳腺癌转移作用的孕甾烷生物碱衍生物及医药用途
US9944590B2 (en) 2015-06-26 2018-04-17 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
US10053415B2 (en) 2016-01-20 2018-08-21 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
WO2019195777A1 (en) 2018-04-06 2019-10-10 Aquinox Pharmaceuticals (Canada) Inc. Indene derivatives useful in treating pain and inflammation
WO2019195692A1 (en) 2018-04-06 2019-10-10 Aquinox Pharmaceuticals (Canada) Inc. Hexadecahydro-1h-cyclopenta[a]phenanthrene derivatives useful in treating pain and inflammation
EP3774746A1 (en) 2018-04-06 2021-02-17 Aquinox Pharmaceuticals (Canada) Inc. Indene derivatives useful in treating pain and inflammation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682983A (en) * 1969-11-12 1972-08-08 Klaus Prezewowsky Preparation of {66 {11 {11 -17 ethinyl steroids
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
CA2073855C (en) 1990-01-18 2007-04-24 Bill Elliot Cham Glycoalkaloids for controlling cellular autophagy
US5877185A (en) 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
CA2086221C (en) * 1992-12-23 2003-07-15 Raymond J. Andersen Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent
DE69412596T2 (de) * 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
WO1996036230A1 (en) 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulators for new members of the steroid/thyroid superfamily of receptors
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
CA2322847C (en) 1998-03-06 2008-05-13 Brigham Young University Steroid derived antibiotics
EP1278763B1 (en) * 2000-04-28 2007-02-14 Inflazyme Pharmaceuticals, Ltd. 3-nitrogen-6,7-dioxygen steroids and uses related thereto

Also Published As

Publication number Publication date
HRP20020944A2 (en) 2004-02-29
ATE353909T1 (de) 2007-03-15
NO20025106D0 (no) 2002-10-24
MXPA02010645A (es) 2004-04-20
DZ3355A1 (fr) 2001-11-08
US20020072510A1 (en) 2002-06-13
NZ522181A (en) 2005-04-29
PL365798A1 (en) 2005-01-10
BG107289A (bg) 2003-07-31
MA25808A1 (fr) 2003-07-01
US20070060553A1 (en) 2007-03-15
US7112580B2 (en) 2006-09-26
AU2001252084B2 (en) 2006-07-06
AU5208401A (en) 2001-11-12
BR0110419A (pt) 2004-02-25
CO5590904A2 (es) 2005-12-30
EP1278763A1 (en) 2003-01-29
EE200200613A (et) 2004-04-15
YU88102A (sh) 2006-01-16
WO2001083512A1 (en) 2001-11-08
OA12255A (en) 2006-05-11
PT1278763E (pt) 2007-05-31
CA2418748A1 (en) 2001-11-08
DE60126597T2 (de) 2007-10-31
KR20030045671A (ko) 2003-06-11
NO20025106L (no) 2002-12-18
ZA200208631B (en) 2004-02-23
RU2291873C2 (ru) 2007-01-20
US20040138186A1 (en) 2004-07-15
US20050215534A9 (en) 2005-09-29
CN1430625A (zh) 2003-07-16
AP1825A (en) 2008-02-03
US6635629B2 (en) 2003-10-21
IL152448A0 (en) 2003-05-29
US20040034216A1 (en) 2004-02-19
HUP0300908A2 (hu) 2003-07-28
JP2003531916A (ja) 2003-10-28
ES2282247T3 (es) 2007-10-16
HK1050694A1 (en) 2003-07-04
SK15692002A3 (sk) 2003-11-04
UA79229C2 (en) 2007-06-11
NO324873B1 (no) 2007-12-17
DK1278763T3 (da) 2007-06-11
AP2002002659A0 (en) 2002-12-31
DE60126597D1 (de) 2007-03-29
IL152448A (en) 2006-12-31
EP1278763B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
CN1214039C (zh) 3－氮－6,7－二氧甾族化合物及其应用
CN1135982C (zh) 含n-酰基-2,3-苯并二氮杂�衍生物的药物组合物的制备方法
CN1057770C (zh) 19,11β－桥甾族化合物在制药中的应用
CN1294142C (zh) 作为抗炎剂的17β－硫代羧酸酯17α－芳基羰氧基雄甾烷衍生物
CN1227236C (zh) 取代的咪唑神经肽yy5受体拮抗剂
CN1319952C (zh) 制备唑烷酮胺的方法
CN100335491C (zh) 具有抗炎活性的大环内酯化合物
CN1269836C (zh) 用于改进抗炎治疗的细胞靶向的免疫细胞特异性大环内酯化合物与抗炎化合物的共轭物
CN1054771A (zh) 17β-取代的-4-氮杂-5α-雄甾烷-3-酮衍生物的制备方法
CN1950334A (zh) 邻位取代的芳基或杂芳基酰胺化合物
CN1400975A (zh) 嘌呤衍生物
CN1768058A (zh) 作为黑皮质素受体激动剂的咪唑并吡啶衍生物
CN1053658C (zh) 氨基芪唑衍生物和药
CN1133296A (zh) 11β-芳基-4-雌烯及其药物上适宜的酸加成盐的制药应用
CN1085224A (zh) 氟化17β-取代的4-氮杂-5α-雄甾烷-3-酮衍生物
CN101048393A (zh) 作为γ－分泌酶抑制剂的取代的N－芳基磺酰基杂环胺
CN1037773C (zh) 含杂原子的三环化合物
CN1922156A (zh) 作为钠通道阻断剂的取代的三唑
CN1018825B (zh) 制备聚-4-氨基吡咯-2-甲酰胺基衍生物的方法
CN1501929A (zh) 新的羟基环己烯基苯基羧酰胺保胎催产素受体拮抗剂
CN101080392A (zh) 作为抗肥胖药剂的哌嗪基吡啶衍生物
CN1158299C (zh) 取代的4-苄基氨基喹啉、其制备方法、含有这些化合物的药物及其应用
CN1279044C (zh) 非甾族孕酮受体调制剂
CN1102529A (zh) 氟化4-氨基雄甾二烯酮衍生物及其制备方法
CN1177354A (zh) 嘧啶并[4,5－b]吲哚

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050810